{"id":"W4375955180","doi":"10.1111/ejh.13982","title":"<scp>PD‐L1</scp> expression predicts efficacy in the phase <scp>II SPiReL</scp> trial with <scp>MVP‐S</scp>, pembrolizumab, and low‐dose <scp>CPA</scp> in R/R <scp>DLBCL</scp>","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Baker Hughes (Canada); McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Oncology; Discontinuation; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.01008957,0.001890835,0.00407878,0.003691712,0.0007930399,0.0004703052,0.002788591,0.0008009998,0.00006909855],"category_scores_gemma":[0.02531009,0.001390473,0.0009630422,0.003803669,0.001619893,0.0009308767,0.001353718,0.005913623,0.0005600016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003916073,"about_ca_system_score_gemma":0.001299534,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004781089,"about_ca_topic_score_gemma":0.00006317897,"domain_scores_codex":[0.9794073,0.006728973,0.004301084,0.002131508,0.00352996,0.003901219],"domain_scores_gemma":[0.9756216,0.01659729,0.002545391,0.002318494,0.000910904,0.002006304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007013968,0.01827087,0.01869203,0.002383996,0.002408414,0.237777,0.08504959,0.001056551,0.1444359,0.0005393943,0.4695556,0.01281676],"study_design_scores_gemma":[0.3701149,0.03097143,0.04392738,0.005726569,0.001196692,0.05563736,0.03159396,0.001667012,0.0385102,0.0004562041,0.4198768,0.0003214299],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9677162,0.004930002,0.000136697,0.0006814289,0.001629353,0.003780146,0.00008085981,0.0003574517,0.02068789],"genre_scores_gemma":[0.9770811,0.003748458,0.0004642903,0.00122541,0.002825842,0.0001424232,0.0001738243,0.0007667362,0.01357193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3631009,"threshold_uncertainty_score":0.9993836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03453579540337291,"score_gpt":0.3144990109351307,"score_spread":0.2799632155317577,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}